Oryzon to invest eur 20 million to develop new drugs
Catalan Economy
10 Sep 2009
Biotech company oryzon genomics has announced a four-year program to invest eur 20 million in the development of new drugs. oryzon ceo carlos buesa indicated that the company would use the resources to strengthen its research on biomarkers and antibody therapy.
oryzon recently opened its new 2,300-square-meter corporate headquarters in cornellà de llobregat (barcelona), with an investment of eur 2.5 million. the company expects revenue of eur 8 million for its current fiscal year.
source: expansión catalunya, 08/09/09
More News and Success Stories.
-
21 May 2026
See more Barcelona ranks among the world’s top three congress cities in the latest ICCA rankingBarcelona ranks among the world’s top three congress cities in the latest ICCA ranking
-
21 May 2026
See more Barcelona strengthens its position as one of the EU’s top five startup hubs for the third consecutive yearBarcelona strengthens its position as one of the EU’s top five startup hubs for the third consecutive year
-
19 May 2026
See more Three Barcelona business schools among the world’s top executive education institutions in the Financial Times global rankingThree Barcelona business schools among the world’s top executive education institutions in the Financial Times global ranking
-
13 May 2026
See more Barcelona Supercomputing Center launches Europe's most advanced open-source chipBarcelona Supercomputing Center launches Europe's most advanced open-source chip
